Our people are the heart of what we do for you

Our people touch every part of what we do as a business, partnering closely with our clients to define and shape the future. Through their unparalleled understanding of the scientific, customer, competitor and market perspectives, they support across every stage of the drug life cycle and beyond. They are the beating heart of the innovations that we develop to meet the needs of our clients in an ever-evolving, ever-changing world.

Talk to our team

Our team

Meet the people who make Prescient unique

Science, strategy and technology may underpin our business, but what drives it are deep, collaborative relationships – we call this ‘True Partnership’. We thrive on building true partnerships where we deeply understand your ambitions, share your vision of the future and see your success as our success.

At Prescient we embody our values. By being collaborative, considered and adaptable we work with you to find solutions that unlock the full potential of your innovation. We always go beyond in service to the partnership and finding the best possible solution.


This is how we see it

The different perspectives we bring to clients help them to focus on the future with clarity of mind. Our blog is written to do exactly the same. Industry insights from the edge of tomorrow.

White Paper

Jun 04, 2024

Navigating Your Medical Narrative: A Proactive Guide

Understanding how medical narratives adapt and transform in response to external events and different phases of a product's life cycle is crucial for effective communication and engagement. This white paper offers valuable insights and practical guidance for navigating these complexities...

Read more

Blog Post

May 23, 2024

How Project Optimus has Reshaped Oncology Drug Development: Opportunities and Challenges

In the wake of the FDA’s Project Optimus, an initiative that aims to reform approaches to dose selection and optimization for oncology drugs, clinical development for cancer therapies is likely to undergo a prolonged and costly transition away from the conventional paradigm...

Read more

White Paper

Apr 25, 2024

Will TL-1A be the Game Changer in IBD? The IBD Treatment Landscape is Still Looking for Answers

Explore the evolving treatment landscape of inflammatory bowel disease (IBD) in our latest white paper. Discover the latest advancements and potential game-changers in patient care...

Read more